Clinical Trial Update: Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a phase 1/2 study evaluating retifanlimab with or without difluoromethylornithine for progressive high-grade gliomas, sponsored by Mayo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Oligodendroglioma
• Astrocytoma Idh-mutant
• Diffuse Astrocytoma
• Glioblastoma Idh-wildtype
• Malignant Glioma

Drugs mentioned

• Difluoromethylornithine (difluoromethylornithine)
• Retifanlimab (retifanlimab)

Snippet

Sponsor: Mayo Clinic | Conditions: Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3 | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING